Form 4: NovaBay Insider Boosts Stake with Major Stock Conversion

R01 Fund LP, a significant insider, has substantially increased its beneficial ownership in NovaBay Pharmaceuticals through preferred stock conversions and warrant issuance.

Summary

• R01 Fund LP converted 220,663 shares of Series D Preferred Stock into 35,306,080 shares of NovaBay Pharmaceuticals' Common Stock.
• R01 Fund LP also converted 134,375 shares of Series E Preferred Stock into 21,500,000 shares of Common Stock.
• A total of 56,806,080 shares of Common Stock were acquired through these conversions, following stockholder approval on October 16, 2025.
• R01 Fund LP was issued 2,702,703 pre-funded warrants to purchase Common Stock on October 16, 2025.
• The pre-funded warrants were purchased at a price of $1.10 per warrant, representing 110% of the prior day's closing price less the $0.01 exercise price.
• The warrants become exercisable after January 1, 2026, subject to future stockholder approval.

Sentiment

Score: 7

Explanation: The significant increase in beneficial ownership by a major investor and insider group (R01 Entities) through preferred stock conversions and warrant issuance indicates strong confidence and a deeper commitment to the company. This also represents a capital infusion for the company. However, the potential for future dilution from warrant exercise is a consideration for existing shareholders.

Positives

• R01 Fund LP significantly increased its direct beneficial ownership of NovaBay Pharmaceuticals common stock to 56,806,080 shares through preferred stock conversions, indicating strong commitment.
• The company secured capital through the issuance of 2,702,703 pre-funded warrants to R01 Fund LP, providing a funding source.
• The transactions reflect continued investment and confidence from a major shareholder and insider group (R01 Entities) in NovaBay Pharmaceuticals.

Risks

• The exercise of the 2,702,703 pre-funded warrants is contingent upon future stockholder approval, introducing uncertainty regarding their full conversion.
• The conversion of preferred stock into 56,806,080 common shares and the potential future exercise of 2,702,703 warrants will result in significant dilution for existing common stockholders.

Future Outlook

Pre-funded warrants issued to R01 Fund LP will become exercisable for common stock after January 1, 2026, contingent upon receiving stockholder approval.

Industry Context

This Form 4 reflects a significant internal capital restructuring and increased insider ownership, which can be interpreted by the market as a vote of confidence from key stakeholders. In the pharmaceutical industry, such moves by major investors can signal strategic alignment or preparation for future growth initiatives, though the filing itself does not detail the underlying strategic rationale.

Corporate Governance

Related Party Transactions

• The transactions involve R01 Fund LP, R01 Capital LLC, R01 Capital Manager LLC, and Michael Kazley, who are identified as related parties and beneficial owners. R01 Capital is the general partner of R01 Fund LP, R01 Capital Manager is the investment manager for R01 Capital, and Michael Kazley is the managing member of R01 Capital Manager, as well as CEO and Director of NovaBay Pharmaceuticals.

Stakeholder Impact

• Shareholders: Experience significant dilution from the conversion of preferred stock into 56,806,080 common shares. Further potential dilution exists from the future exercise of 2,702,703 pre-funded warrants. The R01 Entities' increased ownership could lead to greater influence over company decisions.

Next Steps

• Obtain stockholder approval for the exercise of pre-funded warrants.
• Potential exercise of pre-funded warrants by R01 Fund LP after January 1, 2026.

Key Dates

Keywords

NovaBay Pharmaceuticals, NBY, SEC Form 4, insider trading, beneficial ownership, R01 Fund LP, Michael Kazley, preferred stock conversion, pre-funded warrants, equity financing, corporate governance